Although alpha-fetoprotein (AFP) is commonly used for HCC diagnosis, its limitations in sensitivity and specificity, particularly in early-stage disease16, necessitate alternative or complementary biomarkers. This evidence concerns the gene AFP and hepatocellular carcinoma.